{"log_id": 894295382972797358, "direction": 0, "words_result_num": 101, "words_result": [{"probability": {"variance": 0.000966, "average": 0.984157, "min": 0.872011}, "location": {"width": 301, "top": 132, "height": 34, "left": 741}, "words": "注射用伏立康唑说明书第9页/共13页"}, {"probability": {"variance": 3e-06, "average": 0.998581, "min": 0.994079}, "location": {"width": 153, "top": 175, "height": 22, "left": 174}, "words": "代谢的药物血浓度增高"}, {"probability": {"variance": 0.020004, "average": 0.935646, "min": 0.479664}, "location": {"width": 326, "top": 202, "height": 30, "left": 202}, "words": "特非娜定、阿司咪唑、西沙必利、匹莫齐特和奎"}, {"probability": {"variance": 0.009014, "average": 0.890558, "min": 0.795614}, "location": {"width": 41, "top": 204, "height": 42, "left": 522}, "words": "述药"}, {"probability": {"variance": 0.009635, "average": 0.960122, "min": 0.535117}, "location": {"width": 446, "top": 188, "height": 37, "left": 568}, "words": "CYP3A4底物):尽管未经研究,伏立康唑禁止与特非那定、阿司瞧"}, {"probability": {"variance": 0.027776, "average": 0.916697, "min": 0.442715}, "location": {"width": 218, "top": 209, "height": 31, "left": 695}, "words": "从布导致QT间期延长,并且偶"}, {"probability": {"variance": 4e-06, "average": 0.997075, "min": 0.994299}, "location": {"width": 45, "top": 213, "height": 17, "left": 960}, "words": "尖端扭"}, {"probability": {"variance": 0.019868, "average": 0.928562, "min": 0.49742}, "location": {"width": 339, "top": 225, "height": 26, "left": 175}, "words": "四沙必利、匹英齐特或尼丁合用。因为本品可使"}, {"probability": {"variance": 2.1e-05, "average": 0.996904, "min": 0.986781}, "location": {"width": 90, "top": 224, "height": 18, "left": 562}, "words": "物的血药浓度"}, {"probability": {"variance": 0.000161, "average": 0.99348, "min": 0.95277}, "location": {"width": 185, "top": 249, "height": 19, "left": 174}, "words": "性心动过速(参见【禁忌】)"}, {"probability": {"variance": 0.021432, "average": 0.873769, "min": 0.521068}, "location": {"width": 101, "top": 282, "height": 19, "left": 203}, "words": "西罗莫司CYP3"}, {"probability": {"variance": 0.00177, "average": 0.979595, "min": 0.839191}, "location": {"width": 308, "top": 274, "height": 26, "left": 334}, "words": "底物):与伏立康唑合用时西罗英司(单剂2g)的"}, {"probability": {"variance": 0.001961, "average": 0.968246, "min": 0.884674}, "location": {"width": 127, "top": 270, "height": 19, "left": 686}, "words": "和AUC分别增高"}, {"probability": {"variance": 0.015908, "average": 0.954684, "min": 0.489141}, "location": {"width": 191, "top": 260, "height": 28, "left": 854}, "words": "和1014%。因此禁止这两种药"}, {"probability": {"variance": 0.00566, "average": 0.93036, "min": 0.75907}, "location": {"width": 123, "top": 303, "height": 18, "left": 173}, "words": "物合用(参见【禁忌"}, {"probability": {"variance": 0.009603, "average": 0.943796, "min": 0.650243}, "location": {"width": 468, "top": 325, "height": 32, "left": 202}, "words": "麦角生物城(CYP3A4底物):虽然未经研究,麦角生物碱(变角胺和"}, {"probability": {"variance": 0.007492, "average": 0.961276, "min": 0.721684}, "location": {"width": 227, "top": 317, "height": 27, "left": 714}, "words": "角胺)与伏立康唑合用时血药浓度"}, {"probability": {"variance": 0.020867, "average": 0.937364, "min": 0.421366}, "location": {"width": 452, "top": 346, "height": 31, "left": 174}, "words": "发生麦力中因此禁止伏立康唑与麦角生物碱合用(参见【禁忌】)"}, {"probability": {"variance": 0.007524, "average": 0.968674, "min": 0.478451}, "location": {"width": 839, "top": 366, "height": 44, "left": 203}, "words": "环孢资(CYP3A4底物):在病情稳定的肾移植患者中,伏立康唑可使环孢素的Cmax和AUC至少分别增高13%和70%当已"}, {"probability": {"variance": 0.01056, "average": 0.953049, "min": 0.453119}, "location": {"width": 713, "top": 391, "height": 39, "left": 173}, "words": "经接受环孢紫治疗的患者开始应用本品时,建议其环孢素的剂量减半,并严密监测环孢素的血药浓度。环孢"}, {"probability": {"variance": 1.9e-05, "average": 0.995463, "min": 0.986506}, "location": {"width": 93, "top": 389, "height": 18, "left": 932}, "words": "的增高可引起"}, {"probability": {"variance": 0.018939, "average": 0.940758, "min": 0.49216}, "location": {"width": 508, "top": 418, "height": 32, "left": 174}, "words": "性停用本品后仍严密监测环孢素的浓座,如有需要可大环孢素的剂量"}, {"probability": {"variance": 0.014612, "average": 0.934123, "min": 0.44737}, "location": {"width": 840, "top": 436, "height": 48, "left": 201}, "words": "他克莫(CYP3A4底物):与伏立康唑合用时他克莫司(单剂0.Img/kg)的Cmax和AUC分别增高117%和221%,当已经受"}, {"probability": {"variance": 0.011998, "average": 0.967013, "min": 0.392823}, "location": {"width": 726, "top": 462, "height": 39, "left": 174}, "words": "他克莫司治疗的患者开始使用本品治疗时,建议他充司的剂量减至原来剂量的13,并严密监测血浓度。他"}, {"probability": {"variance": 0.007058, "average": 0.967633, "min": 0.716042}, "location": {"width": 150, "top": 500, "height": 20, "left": 174}, "words": "肾毒性,停用本品后仍"}, {"probability": {"variance": 0.00215, "average": 0.974543, "min": 0.836442}, "location": {"width": 185, "top": 495, "height": 21, "left": 357}, "words": "密监测他克莫司的浓度,如"}, {"probability": {"variance": 0.000274, "average": 0.980609, "min": 0.964042}, "location": {"width": 28, "top": 492, "height": 16, "left": 631}, "words": "他克"}, {"probability": {"variance": 0.012473, "average": 0.929976, "min": 0.736647}, "location": {"width": 57, "top": 532, "height": 18, "left": 196}, "words": "及抗凝剂"}, {"probability": {"variance": 0.006432, "average": 0.966907, "min": 0.535268}, "location": {"width": 480, "top": 552, "height": 34, "left": 203}, "words": "华法令(CYP2C9底物):伏立康唑(每日2次,每次0.3g)与华法令(单剂"}, {"probability": {"variance": 0.001344, "average": 0.979187, "min": 0.885197}, "location": {"width": 127, "top": 549, "height": 20, "left": 737}, "words": "合用凝血酶原时间"}, {"probability": {"variance": 0.0306, "average": 0.924918, "min": 0.433434}, "location": {"width": 125, "top": 541, "height": 24, "left": 912}, "words": "延长93%因此当"}, {"probability": {"variance": 0.000418, "average": 0.979395, "min": 0.930048}, "location": {"width": 257, "top": 582, "height": 22, "left": 174}, "words": "者合用时,建议严密监测凝血酶原时间"}, {"probability": {"variance": 0.003034, "average": 0.974162, "min": 0.690728}, "location": {"width": 838, "top": 593, "height": 44, "left": 203}, "words": "其他口服抗凝剂,如苯丙羟基香豆素和醋硝香豆素(CYP2C9和CYP3A4底物):虽然未经研究,香豆素类与伏立康唑合用时"}, {"probability": {"variance": 9.7e-05, "average": 0.993669, "min": 0.964592}, "location": {"width": 204, "top": 631, "height": 22, "left": 196}, "words": "血浓度可能增高,从而延长凝"}, {"probability": {"variance": 0.000562, "average": 0.985995, "min": 0.910058}, "location": {"width": 191, "top": 625, "height": 22, "left": 497}, "words": "如果Cmax者同时应用伏立"}, {"probability": {"variance": 0.003663, "average": 0.97037, "min": 0.792692}, "location": {"width": 197, "top": 618, "height": 24, "left": 736}, "words": "香豆素制剂,需要密切监测凝"}, {"probability": {"variance": 0.000232, "average": 0.988921, "min": 0.956822}, "location": {"width": 137, "top": 652, "height": 20, "left": 174}, "words": "此调整抗凝剂的剂量"}, {"probability": {"variance": 0.007262, "average": 0.968182, "min": 0.633447}, "location": {"width": 469, "top": 673, "height": 34, "left": 207}, "words": "黄脲类(CYP2C9的底物):虽然未进行研究,同时应用时伏立康唑可能"}, {"probability": {"variance": 9.8e-05, "average": 0.995968, "min": 0.963305}, "location": {"width": 185, "top": 668, "height": 24, "left": 736}, "words": "类药物的血药浓度(如甲苯"}, {"probability": {"variance": 0.002552, "average": 0.984201, "min": 0.723205}, "location": {"width": 446, "top": 696, "height": 31, "left": 180}, "words": "各列本脲),从而引起低血糖症。因此两者合用时建议密切监测血糖"}, {"probability": {"variance": 0.010031, "average": 0.961923, "min": 0.425069}, "location": {"width": 833, "top": 714, "height": 45, "left": 202}, "words": "他汀类CYP3A4的底物):虽然未经临床研究,体外试验(人肝微粒体)已证明伏立康唑对洛伐他汀的代谢有抑制作用。因"}, {"probability": {"variance": 0.005564, "average": 0.972758, "min": 0.562801}, "location": {"width": 862, "top": 736, "height": 43, "left": 173}, "words": "伏立康唑与他汀类合用可能会使通过CYP3A4代谢的他汀类药物血药浓度增高。他汀类药物的血药浓度增高可能引起横纹肌溶督"}, {"probability": {"variance": 0.00163, "average": 0.970473, "min": 0.838563}, "location": {"width": 265, "top": 773, "height": 26, "left": 174}, "words": "建议两者合用时他汀类的剂量应予调整"}, {"probability": {"variance": 0.009207, "average": 0.966316, "min": 0.445602}, "location": {"width": 838, "top": 785, "height": 45, "left": 202}, "words": "苯二氮卓类(CYP3A4底物):尽管未经临床研究,伏立糜唑在体外(肝微粒体)已显示对咪达唑仑的代谢有抑制作用。因此"}, {"probability": {"variance": 0.000526, "average": 0.988634, "min": 0.890501}, "location": {"width": 571, "top": 815, "height": 35, "left": 174}, "words": "伏立康唑可能使经CYP3A4代谢的苯二氮卓类药物(咪哒唑仑和三唑仑)血药浓度增"}, {"probability": {"variance": 0.001742, "average": 0.97988, "min": 0.877812}, "location": {"width": 106, "top": 813, "height": 18, "left": 777}, "words": "镇静作用时间延"}, {"probability": {"variance": 0.060522, "average": 0.841584, "min": 0.376831}, "location": {"width": 126, "top": 807, "height": 23, "left": 921}, "words": "议两药合用时整"}, {"probability": {"variance": 6e-06, "average": 0.997732, "min": 0.993599}, "location": {"width": 93, "top": 848, "height": 19, "left": 203}, "words": "氮卓类药物的"}, {"probability": {"variance": 0.009332, "average": 0.961324, "min": 0.454747}, "location": {"width": 620, "top": 864, "height": 36, "left": 202}, "words": "长春花生物碱(CYP3A4底物):虽然未经研究,与伏立康唑合用,长春花生物碱(长春新碱"}, {"probability": {"variance": 9e-06, "average": 0.997426, "min": 0.990449}, "location": {"width": 107, "top": 860, "height": 19, "left": 917}, "words": "的血药浓度仍有"}, {"probability": {"variance": 0.001002, "average": 0.986884, "min": 0.903199}, "location": {"width": 157, "top": 897, "height": 23, "left": 188}, "words": "能,从而产生经性"}, {"probability": {"variance": 0.000378, "average": 0.983963, "min": 0.936569}, "location": {"width": 209, "top": 923, "height": 30, "left": 205}, "words": "强的松(CYP3A4底物):与伏"}, {"probability": {"variance": 0.000111, "average": 0.992019, "min": 0.963482}, "location": {"width": 157, "top": 921, "height": 23, "left": 458}, "words": "合用时强的松(单剂60"}, {"probability": {"variance": 0.002617, "average": 0.970718, "min": 0.810982}, "location": {"width": 386, "top": 909, "height": 28, "left": 647}, "words": "的Cmax和AUC分别增高11%和34%两者合用时均无"}, {"probability": {"variance": 0.063188, "average": 0.852723, "min": 0.417355}, "location": {"width": 54, "top": 952, "height": 17, "left": 174}, "words": "调整剂"}, {"probability": {"variance": 0.016656, "average": 0.938497, "min": 0.532511}, "location": {"width": 257, "top": 974, "height": 29, "left": 201}, "words": "地高新(P-糖蛋白介导转运):伏立"}, {"probability": {"variance": 4.4e-05, "average": 0.99507, "min": 0.980661}, "location": {"width": 107, "top": 970, "height": 22, "left": 546}, "words": "每日1次,每次"}, {"probability": {"variance": 0.002877, "average": 0.965702, "min": 0.809008}, "location": {"width": 208, "top": 962, "height": 24, "left": 720}, "words": "的Cmax和AC无显著影响"}, {"probability": {"variance": 0.025671, "average": 0.90528, "min": 0.450422}, "location": {"width": 353, "top": 1006, "height": 28, "left": 202}, "words": "麦考酚酸(UDP-葡带糖醛酰基转移酶底物):伏立糜"}, {"probability": {"variance": 0, "average": 0.786738, "min": 0.786738}, "location": {"width": 19, "top": 1005, "height": 19, "left": 615}, "words": "盼"}, {"probability": {"variance": 0.009685, "average": 0.948124, "min": 0.710532}, "location": {"width": 94, "top": 1045, "height": 20, "left": 174}, "words": "两药相互作用:"}, {"probability": {"variance": 0.031337, "average": 0.71635, "min": 0.384774}, "location": {"width": 318, "top": 1017, "height": 43, "left": 633}, "words": "受理号ouJ"}, {"probability": {"variance": 0.012024, "average": 0.900137, "min": 0.674006}, "location": {"width": 137, "top": 1076, "height": 21, "left": 202}, "words": "苯妥英(CYP2C9底"}, {"probability": {"variance": 0.026019, "average": 0.813302, "min": 0.54942}, "location": {"width": 144, "top": 1054, "height": 37, "left": 411}, "words": "的强高,应"}, {"probability": {"variance": 0.012724, "average": 0.945252, "min": 0.672208}, "location": {"width": 110, "top": 1107, "height": 21, "left": 203}, "words": "苯妥英每日1次"}, {"probability": {"variance": 1e-06, "average": 0.998419, "min": 0.997235}, "location": {"width": 60, "top": 1103, "height": 19, "left": 397}, "words": "可使伏立"}, {"probability": {"variance": 0.028376, "average": 0.927881, "min": 0.437029}, "location": {"width": 136, "top": 1128, "height": 18, "left": 175}, "words": "用量),可使苯妥英"}, {"probability": {"variance": 0.009239, "average": 0.941699, "min": 0.750519}, "location": {"width": 54, "top": 1127, "height": 17, "left": 419}, "words": "次0.38"}, {"probability": {"variance": 0, "average": 0.99651, "min": 0.99651}, "location": {"width": 16, "top": 1153, "height": 15, "left": 175}, "words": "浓"}, {"probability": {"variance": 3e-06, "average": 0.997872, "min": 0.995817}, "location": {"width": 91, "top": 1140, "height": 36, "left": 385}, "words": "丽珠制"}, {"probability": {"variance": 0.100942, "average": 0.670143, "min": 0.35243}, "location": {"width": 32, "top": 1170, "height": 21, "left": 482}, "words": "的"}, {"probability": {"variance": 0.046724, "average": 0.698211, "min": 0.386276}, "location": {"width": 121, "top": 1148, "height": 37, "left": 641}, "words": "收务的:"}, {"probability": {"variance": 0.0125, "average": 0.920718, "min": 0.662057}, "location": {"width": 177, "top": 1173, "height": 27, "left": 216}, "words": "苯妥英合用时,需要适当"}, {"probability": {"variance": 0.009574, "average": 0.958043, "min": 0.674276}, "location": {"width": 184, "top": 1193, "height": 28, "left": 203}, "words": "每次0.4g;如患者体重小于"}, {"probability": {"variance": 0.018832, "average": 0.919351, "min": 0.681675}, "location": {"width": 58, "top": 1192, "height": 17, "left": 544}, "words": "次,每次"}, {"probability": {"variance": 0, "average": 0.999961, "min": 0.99994}, "location": {"width": 27, "top": 1220, "height": 17, "left": 217}, "words": "每次"}, {"probability": {"variance": 1.7e-05, "average": 0.994044, "min": 0.987544}, "location": {"width": 123, "top": 1214, "height": 20, "left": 314}, "words": "参见【用法用量】"}, {"probability": {"variance": 0.007489, "average": 0.959399, "min": 0.651674}, "location": {"width": 622, "top": 1232, "height": 41, "left": 202}, "words": "利布工(CYP450诱导剂):应尽量避免利福布丁和伏立康唑合用,除非经权衡后利大于弊"}, {"probability": {"variance": 0.002686, "average": 0.955695, "min": 0.87174}, "location": {"width": 90, "top": 1279, "height": 27, "left": 207}, "words": "司时应用利福"}, {"probability": {"variance": 0.005665, "average": 0.966198, "min": 0.527627}, "location": {"width": 769, "top": 1257, "height": 46, "left": 280}, "words": "福布丁(每日1次,每次0.3g)和伏立康唑(每日2次,每次0.2g),伏立康唑的Cmax和AUC分别降低69%和78%"}, {"probability": {"variance": 0.005539, "average": 0.976896, "min": 0.603818}, "location": {"width": 384, "top": 1294, "height": 31, "left": 174}, "words": "伏立糜唑每日给药2次,每次0.35g与利福布丁合用,其"}, {"probability": {"variance": 0.00996, "average": 0.962173, "min": 0.481473}, "location": {"width": 425, "top": 1278, "height": 33, "left": 623}, "words": "UCT分别为单独用药(每日2次,每次0.2g)时的96%和6%"}, {"probability": {"variance": 0.008251, "average": 0.962866, "min": 0.56999}, "location": {"width": 381, "top": 1314, "height": 31, "left": 174}, "words": "伏立糜唑每口给药2次,每次0.4g,与利布丁合用,其"}, {"probability": {"variance": 0.006048, "average": 0.972048, "min": 0.612942}, "location": {"width": 326, "top": 1304, "height": 28, "left": 597}, "words": "和AUCt分别较单独用药(每日2次,每次0.2g"}, {"probability": {"variance": 0.000322, "average": 0.989568, "min": 0.930265}, "location": {"width": 326, "top": 1336, "height": 31, "left": 175}, "words": "同时利福布丁的和AUC分别增高了195%和33"}, {"probability": {"variance": 0.00512, "average": 0.979935, "min": 0.496262}, "location": {"width": 752, "top": 1354, "height": 44, "left": 204}, "words": "利福布丁与伏立康唑同时应用时,建议增加伏立糜唑的维持剂量。如为口服给药,剂量从每日2次,每次0.2g"}, {"probability": {"variance": 0.002752, "average": 0.975139, "min": 0.789189}, "location": {"width": 329, "top": 1374, "height": 30, "left": 657}, "words": "增高至每日2次;每次0.2g如为静脉滴注,剂"}, {"probability": {"variance": 0.016805, "average": 0.933721, "min": 0.51228}, "location": {"width": 192, "top": 1394, "height": 24, "left": 175}, "words": "次,每次035g:如患者体重"}, {"probability": {"variance": 0.016067, "average": 0.953075, "min": 0.48643}, "location": {"width": 205, "top": 1388, "height": 19, "left": 405}, "words": "0kg,则剂量从每日2次,每次"}, {"probability": {"variance": 0.011641, "average": 0.960721, "min": 0.476967}, "location": {"width": 450, "top": 1405, "height": 35, "left": 175}, "words": "日2次,每次5mg/kg.井监测全血细胞计数和利福布丁的不良事件"}, {"probability": {"variance": 0.046502, "average": 0.845863, "min": 0.540904}, "location": {"width": 44, "top": 1403, "height": 18, "left": 673}, "words": "萄膜炎"}, {"probability": {"variance": 0.001256, "average": 0.975158, "min": 0.824404}, "location": {"width": 398, "top": 1439, "height": 33, "left": 202}, "words": "奥美拉唑(CYP2C19抑制剂,CYP2C19和CYP3A4底物"}, {"probability": {"variance": 0.001681, "average": 0.98408, "min": 0.783244}, "location": {"width": 368, "top": 1424, "height": 33, "left": 666}, "words": "拉唑(每日单剂40mg)同时应用时,伏立康唑的Cma"}, {"probability": {"variance": 0.006481, "average": 0.969716, "min": 0.604747}, "location": {"width": 331, "top": 1460, "height": 31, "left": 219}, "words": "分别增高15%和41%.无需调整伏立康唑的剂量"}, {"probability": {"variance": 0.000721, "average": 0.979996, "min": 0.898518}, "location": {"width": 202, "top": 1497, "height": 26, "left": 204}, "words": "与伏立康唑合用时奥美拉唑的"}, {"probability": {"variance": 0.013739, "average": 0.939578, "min": 0.656441}, "location": {"width": 96, "top": 1494, "height": 22, "left": 454}, "words": "和AUCi分别"}, {"probability": {"variance": 2e-06, "average": 0.997685, "min": 0.995958}, "location": {"width": 36, "top": 1491, "height": 20, "left": 615}, "words": "和28"}, {"probability": {"variance": 0.000496, "average": 0.990004, "min": 0.905342}, "location": {"width": 248, "top": 1480, "height": 30, "left": 686}, "words": "因此当正在服用奥美拉唑者开始服用"}, {"probability": {"variance": 0.000767, "average": 0.971843, "min": 0.94414}, "location": {"width": 29, "top": 1526, "height": 17, "left": 175}, "words": "将奥"}, {"probability": {"variance": 0.014547, "average": 0.911497, "min": 0.706344}, "location": {"width": 59, "top": 1524, "height": 17, "left": 253}, "words": "的剂量减"}, {"probability": {"variance": 0.001462, "average": 0.981645, "min": 0.896168}, "location": {"width": 53, "top": 1595, "height": 21, "left": 498}, "words": "362-02"}], "language": 3}